U.S. markets close in 6 hours 2 minutes

Lucira Health, Inc. (LHDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.49+0.03 (+0.40%)
As of 9:57AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close7.46
Open7.49
Bid7.43 x 800
Ask7.55 x 1200
Day's Range7.36 - 7.53
52 Week Range7.25 - 37.99
Volume23,642
Avg. Volume775,576
Market Cap303.324M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Covid Test Maker Cue Health Taps Morgan Stanley, Goldman for IPO
      Bloomberg

      Covid Test Maker Cue Health Taps Morgan Stanley, Goldman for IPO

      (Bloomberg) -- Covid test maker Cue Health Inc. is planning an initial public offering as soon as this year, according to people with knowledge of the matter.The health-care technology company is working with banks including Morgan Stanley and Goldman Sachs Group Inc. on a listing, said the people, who asked not to be identified discussing information that isn’t yet public.The company’s plans, including the timing of an IPO, could still change.A spokesperson for Cue Health didn’t immediately respond to a request for comment. Representatives for Morgan Stanley and Goldman Sachs declined to comment.Cue Health’s tests were used last year by the National Basketball Association to help limit the spread of the coronavirus among team members who played and lived in a so-called bubble in Florida.The U.S. Department of Health and Human Services in October said it would invest $481 million in the San Diego-based company to boost manufacturing of the tests, which processes results in about 20 minutes. Last month, the tests were given emergency approval by the U.S. Food and Drug Administration for home and over-the-counter use.Venture BackersCue Health, led by co-founder and Chief Executive Officer Ayub Khattak, raised $100 million last June from investors including Madrone Capital Partners, Johnson & Johnson Innovation, Decheng Capital and Foresite Capital. The Information reported in December that the company had discussed raising new funding that could have boosted its valuation above $2 billion.The company’s Covid-19 tests are being used in 10 U.S. states at schools, nursing homes and hospitals, among other places. Cue Health has said it’s also working on at-home influenza testing.Last month, it named John Gallagher, a former Becton Dickinson & Co. executive, as chief financial officer. It also hired ex-Livongo executive Erica Palsis as general counsel.Health-care companies focused on coronavirus testing are increasingly turning to public markets to fund growth.LumiraDx, LuciraLumiraDx Ltd. last week agreed to go public through a merger with a special purpose acquisition company. Lucira Health Inc., which went public in February, saw its stock spike this week after its home-testing kit received FDA approval.Hong Kong-based Prenetics Ltd., whose Covid-19 tests were used by the English Premier League, is also planning an IPO, Nikkei has reported.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

    • Why Lucira Health Stock Is Plunging Today
      Motley Fool

      Why Lucira Health Stock Is Plunging Today

      After rising sharply on Monday, shares of medical technology company Lucira Health (NASDAQ: LHDX) are going in the opposite direction on Tuesday. Lucira Health did not report any news today, but we can attribute its woes on the stock market to bearish commentary from a Wall Street analyst. Bank of America analyst Derik de Bruin downgraded Lucira Health's stock to underperform from buy.

    • Why Lucira Health Stock Skyrocketed Today
      Motley Fool

      Why Lucira Health Stock Skyrocketed Today

      The company's COVID-19 Test Kit will soon be available for sale at a pharmacy near you.